DE3916112A1 - Dihydrospirorenon als antiandrogen - Google Patents
Dihydrospirorenon als antiandrogenInfo
- Publication number
- DE3916112A1 DE3916112A1 DE3916112A DE3916112A DE3916112A1 DE 3916112 A1 DE3916112 A1 DE 3916112A1 DE 3916112 A DE3916112 A DE 3916112A DE 3916112 A DE3916112 A DE 3916112A DE 3916112 A1 DE3916112 A1 DE 3916112A1
- Authority
- DE
- Germany
- Prior art keywords
- compound
- formula
- estrogen
- treatment
- hormonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002280 anti-androgenic effect Effects 0.000 title description 4
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 title description 3
- 229960004845 drospirenone Drugs 0.000 title description 3
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 title description 3
- 239000000051 antiandrogen Substances 0.000 title 1
- 239000000262 estrogen Substances 0.000 claims abstract description 16
- 230000003054 hormonal effect Effects 0.000 claims abstract description 8
- 230000009245 menopause Effects 0.000 claims abstract description 5
- 239000003098 androgen Substances 0.000 claims abstract description 4
- 230000006641 stabilisation Effects 0.000 claims abstract description 4
- 229940011871 estrogen Drugs 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000011105 stabilization Methods 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 7
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003433 contraceptive agent Substances 0.000 description 4
- 230000002254 contraceptive effect Effects 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003152 gestagenic effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical group O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 206010047486 Virilism Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002170 aldosterone antagonist Substances 0.000 description 2
- 230000001864 anti-aldosterone effect Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940127234 oral contraceptive Drugs 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3916112A DE3916112A1 (de) | 1989-05-16 | 1989-05-16 | Dihydrospirorenon als antiandrogen |
| DD90340683A DD294417A5 (de) | 1989-05-16 | 1990-05-15 | Verwendung von verbindungen zur herstellung eines arzneimittels |
| PT94038A PT94038B (pt) | 1989-05-16 | 1990-05-15 | Processo para a preparacao de composicoes farmaceuticas que contem di-hidroespirorenona como antiandrogenio |
| CA002016780A CA2016780C (en) | 1989-05-16 | 1990-05-15 | Dihydrospirorenone as an antiandrogen |
| HU903045A HU213408B (en) | 1989-05-16 | 1990-05-15 | Process for producing pharmaceutical compositions comprising drospirenon |
| IE173890A IE81143B1 (en) | 1989-05-16 | 1990-05-15 | Dihydrospirorenone as an antiandrogen |
| AT90250127T ATE154881T1 (de) | 1989-05-16 | 1990-05-16 | Dihydrospirorenon als antiandrogen |
| ZA903754A ZA903754B (en) | 1989-05-16 | 1990-05-16 | Dihydrospirorenone as an antioandrogen |
| DE1990510730 DE122004000006I1 (de) | 1989-05-16 | 1990-05-16 | Dihydrospirorenon als Antiandrogen |
| CN90103713A CN1033948C (zh) | 1989-05-16 | 1990-05-16 | 二氢螺旋烯酮在制备药物组合物中的应用 |
| EP90250127A EP0398460B1 (de) | 1989-05-16 | 1990-05-16 | Dihydrospirorenon als Antiandrogen |
| DK90250127.9T DK0398460T3 (da) | 1989-05-16 | 1990-05-16 | Anvendelse af dihydrospirorenon som anti-androgen |
| IL94416A IL94416A (en) | 1989-05-16 | 1990-05-16 | Pharmaceutical compositions containing dihydrospirorenone |
| AU55094/90A AU642876B2 (en) | 1989-05-16 | 1990-05-16 | Dihydrospirorenone as an antiandrogen |
| JP2124308A JP2848919B2 (ja) | 1989-05-16 | 1990-05-16 | 前更年期のホルモン異常の治療用、更年期のホルモン補充療法用、アンドロゲン誘引性障害の治療用および避妊用医薬 |
| LU91065C LU91065I2 (fr) | 1989-05-16 | 1990-05-16 | Drospirenone en combinaison avec oestradiol et leurs dérivés pharmaceutiquement acceptables (Allurene-Angeliq) |
| ES90250127T ES2106728T3 (es) | 1989-05-16 | 1990-05-16 | Dihidroespirorenona como agente antiandrogeno. |
| DE59010730T DE59010730D1 (de) | 1989-05-16 | 1990-05-16 | Dihydrospirorenon als Antiandrogen |
| US08/162,387 US5569652A (en) | 1989-05-16 | 1993-12-07 | Dihydrospirorenone as an antiandrogen |
| BR1101055-0A BR1101055A (pt) | 1989-05-16 | 1997-05-14 | Dihidroespirorenona como antiandrogênio |
| GR970402505T GR3024861T3 (en) | 1989-05-16 | 1997-09-24 | Use of dihydrospirorenone as an anti-androgen |
| NL300221C NL300221I2 (nl) | 1989-05-16 | 2006-02-03 | Dihydrospirorenon als anti-androgeen. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3916112A DE3916112A1 (de) | 1989-05-16 | 1989-05-16 | Dihydrospirorenon als antiandrogen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3916112A1 true DE3916112A1 (de) | 1990-11-22 |
| DE3916112C2 DE3916112C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-04-30 |
Family
ID=6380839
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3916112A Granted DE3916112A1 (de) | 1989-05-16 | 1989-05-16 | Dihydrospirorenon als antiandrogen |
| DE1990510730 Pending DE122004000006I1 (de) | 1989-05-16 | 1990-05-16 | Dihydrospirorenon als Antiandrogen |
| DE59010730T Expired - Lifetime DE59010730D1 (de) | 1989-05-16 | 1990-05-16 | Dihydrospirorenon als Antiandrogen |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1990510730 Pending DE122004000006I1 (de) | 1989-05-16 | 1990-05-16 | Dihydrospirorenon als Antiandrogen |
| DE59010730T Expired - Lifetime DE59010730D1 (de) | 1989-05-16 | 1990-05-16 | Dihydrospirorenon als Antiandrogen |
Country Status (20)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4321957A1 (de) * | 1993-07-01 | 1995-01-12 | Marika Dr Med Ehrlich | Hormonales Mittel zur Therapie der Akne und dessen Verwendung |
| WO1998024801A1 (de) * | 1996-12-01 | 1998-06-11 | Schering Aktiengesellschaft | Oxyiminopregnancarbolactone |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4344462C2 (de) | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| ES2211580T3 (es) * | 1999-08-31 | 2004-07-16 | Schering Aktiengesellschaft | Combinacion farmaceutica de etinilestradiol y drospirenona para uso como anticonceptivo. |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| EP2305267A3 (en) | 1999-08-31 | 2011-08-17 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| EP1353699B1 (en) * | 2000-12-20 | 2012-02-01 | Bayer Pharma Aktiengesellschaft | Beta-cyclodextrin-drospirenone inclusion complexes |
| EP1216712A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| CA2479259A1 (en) * | 2002-03-18 | 2003-10-02 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a bile acid sequestering agent |
| CN1642557A (zh) * | 2002-03-18 | 2005-07-20 | 法玛西雅公司 | 醛固酮受体拮抗剂与烟酸或烟酸衍生物的组合 |
| WO2004070048A1 (en) * | 2003-02-07 | 2004-08-19 | Pharmacia & Upjohn Company Llc | A microbial process to prepare 5-androsten-3beta, 7alpha, 15alpha-triol-17-one and related analogues |
| US20050220825A1 (en) * | 2004-03-10 | 2005-10-06 | Adrian Funke | Molecular dispersions of drospirenone |
| MY142989A (en) * | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
| PT1748756E (pt) * | 2004-03-10 | 2009-07-20 | Bayer Schering Pharma Ag | Composições compreendendo drospirenona molecularmente dispersa |
| DE102004026670A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| DE102004026679A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| DE102004026671A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Darreichungsform zur hormonalen Kontrazeption |
| DE102004026669A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels |
| ITMI20042338A1 (it) * | 2004-12-06 | 2005-03-06 | Ind Chimica Srl | Processo per la preparazione di drospirenone |
| US8475838B2 (en) * | 2005-06-03 | 2013-07-02 | Sandoz Ag | Rapidly-dissolving pharmaceutical composition for inhibiting ovulation |
| SI1746101T2 (sl) * | 2005-07-21 | 2014-09-30 | Bayer Pharma Aktiengesellschaft | Postopek za pripravo 3-okso-pregn-4-en-21,17-karbolaktonov z oksidacijo 17-(3-hidroksipropil)-3,17-dihidroksiandrostanov brez uporabe kovine |
| US7319154B2 (en) | 2005-07-21 | 2008-01-15 | Bayer Schering Pharma Ag | Process for the production of 3-oxo-pregn-4-ene-21, 17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3, 17-dihydroxyandrostanes |
| US20070275941A1 (en) * | 2006-05-17 | 2007-11-29 | Vladimir Hanes | Salt sensitivity and prevention of hypertension with drospirenone |
| CN102083418A (zh) * | 2008-04-24 | 2011-06-01 | 伊万斯彻有限公司 | 口服避孕药剂及其制备方法 |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | 天然の併用ホルモン補充療法剤及び療法 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3022337A1 (de) * | 1980-06-11 | 1982-01-07 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2652761C2 (de) * | 1976-11-16 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| US4347245A (en) * | 1981-05-26 | 1982-08-31 | German Shapiro | Spironolactone-containing composition and use thereof |
| JPS59139400A (ja) * | 1983-01-31 | 1984-08-10 | Shionogi & Co Ltd | 抗アルドステロン活性ステロイド誘導体 |
| DE3402329A1 (de) * | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| US4855289A (en) * | 1984-06-04 | 1989-08-08 | Wester Per O | Combination of two active substances |
| US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
| DE3615376A1 (de) * | 1986-05-07 | 1987-11-12 | Schering Ag | 2,2;6,6-diethylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| DK174724B1 (da) * | 1986-07-15 | 2003-10-06 | Wyeth Corp | Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet |
-
1989
- 1989-05-16 DE DE3916112A patent/DE3916112A1/de active Granted
-
1990
- 1990-05-15 HU HU903045A patent/HU213408B/hu unknown
- 1990-05-15 PT PT94038A patent/PT94038B/pt not_active IP Right Cessation
- 1990-05-15 CA CA002016780A patent/CA2016780C/en not_active Expired - Lifetime
- 1990-05-15 IE IE173890A patent/IE81143B1/en not_active IP Right Cessation
- 1990-05-15 DD DD90340683A patent/DD294417A5/de not_active IP Right Cessation
- 1990-05-16 IL IL94416A patent/IL94416A/xx not_active IP Right Cessation
- 1990-05-16 DE DE1990510730 patent/DE122004000006I1/de active Pending
- 1990-05-16 ES ES90250127T patent/ES2106728T3/es not_active Expired - Lifetime
- 1990-05-16 EP EP90250127A patent/EP0398460B1/de not_active Expired - Lifetime
- 1990-05-16 LU LU91065C patent/LU91065I2/fr unknown
- 1990-05-16 CN CN90103713A patent/CN1033948C/zh not_active Expired - Lifetime
- 1990-05-16 AU AU55094/90A patent/AU642876B2/en not_active Expired
- 1990-05-16 DE DE59010730T patent/DE59010730D1/de not_active Expired - Lifetime
- 1990-05-16 DK DK90250127.9T patent/DK0398460T3/da active
- 1990-05-16 AT AT90250127T patent/ATE154881T1/de active
- 1990-05-16 ZA ZA903754A patent/ZA903754B/xx unknown
- 1990-05-16 JP JP2124308A patent/JP2848919B2/ja not_active Expired - Lifetime
-
1993
- 1993-12-07 US US08/162,387 patent/US5569652A/en not_active Expired - Lifetime
-
1997
- 1997-05-14 BR BR1101055-0A patent/BR1101055A/pt active Search and Examination
- 1997-09-24 GR GR970402505T patent/GR3024861T3/el unknown
-
2006
- 2006-02-03 NL NL300221C patent/NL300221I2/nl unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3022337A1 (de) * | 1980-06-11 | 1982-01-07 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen |
Non-Patent Citations (1)
| Title |
|---|
| NEUMANN, F. et al.: Androgens II and Anti- androgens, Berlin 1974, Springer-Verlag, S. 422 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4321957A1 (de) * | 1993-07-01 | 1995-01-12 | Marika Dr Med Ehrlich | Hormonales Mittel zur Therapie der Akne und dessen Verwendung |
| WO1998024801A1 (de) * | 1996-12-01 | 1998-06-11 | Schering Aktiengesellschaft | Oxyiminopregnancarbolactone |
| US6177416B1 (en) * | 1996-12-01 | 2001-01-23 | Schering Aktiengesellschaft | Oxyiminopregnancarbolactones |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0398460B1 (de) | Dihydrospirorenon als Antiandrogen | |
| DE69804918T2 (de) | Sehr niedrigdosiertes orales Kontrazeptiv mit weniger Menstruationsblutungen und verzögerter Wirkung | |
| EP0696454B1 (de) | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente | |
| EP1011682B1 (de) | Mittel zur hormonalen kontrazeption | |
| EP0148724B1 (de) | Mehrstufenkombinationspräparat und seine Verwendung zur oralen Kontrazeption | |
| DE69118494T2 (de) | Kontrazeptionsverfahren und Schema | |
| EP0628312B1 (de) | Kombinationspräparat zur Kontrazeption | |
| EP0835114B1 (de) | Pharmazeutisches kombinationspräparat, kit und methode zur hormonalen kontrazeption | |
| DE4429398C2 (de) | Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption | |
| DE69729956T2 (de) | Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält | |
| DE19654609A1 (de) | Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder | |
| DE3022337C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| WO1996019997A1 (de) | Progesteronantagonistisch- und antiöstrogen wirksame verbindungen zur gemeinsamen verwendung für die weibliche kontrazeption | |
| EP0787002B1 (de) | Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle | |
| EP0871453A1 (de) | Pharmazeutisches kombinationspräparat zur hormonalen kontrazeption | |
| DE2431704A1 (de) | Stufenkombinationspraeparate per kontrazeption | |
| DE602004009288T2 (de) | Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose | |
| DE69724796T2 (de) | Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten | |
| DE2431694A1 (de) | Kontrzeptionsmittel und kontrazeptivumpackung | |
| DD238921A5 (de) | Verfahren zur herstellung einer kontrazeptiven synergistischen zusammensetzung | |
| DE4216004B4 (de) | Verwendung kompetitiver Progesteronantagonisten | |
| DE102006003508A1 (de) | Arzneimittel umfassend eine Hormonkombination | |
| DE1922005A1 (de) | Mittel und Methode zur Kontrazeption | |
| WO1996028165A1 (de) | Einmonatsspritze als depot-kontrazeptivum und für die hormonersatztherapie für peri- und praemenopausale frauen | |
| DE2319850A1 (de) | Verfahren zur fruchtbarkeitskontrolle und abgabepackung zu seiner durchfuehrung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: SCHERING AG, 13353 BERLIN, DE |
|
| 8330 | Complete renunciation |